Loading
A phase 3 trial of Pembrolizumab, Sacituzumab tirumotecan, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]. ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 851 participants. Primary completion is estimated at 2029-01-12. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel. Registered primary measures: Overall survival (OS).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Paclitaxel / nab-paclitaxel.
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares Sacituzumab tirumotecan, TROP2, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD).
Shares TROP2, Topoisomerase-I inhibitors (and ADC payloads), Platinum agents, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/